Please login to the form below

Not currently logged in
Email:
Password:

Lenvima

This page shows the latest Lenvima news and features for those working in and with pharma, biotech and healthcare.

Merck spins off low-growth drugs in a ‘purposeful shift’ of focus

Merck spins off low-growth drugs in a ‘purposeful shift’ of focus

Responding to these concerns, Frazier said that the company are “mindful” of the issues that have been raised around Keytruda, also adding that “we have more than Keytruda, we have Lenvima

Latest news

  • Roche’s Tecentriq/Avastin combo improves survival in liver cancer Roche’s Tecentriq/Avastin combo improves survival in liver cancer

    Merck is testing Keytruda alongside partner Eisai’s kinase inhibitor Lenvima (lenvatinib) – already-approved for first-line HCC – in the Leap-002 trial, picking up a breakthrough designation from the FDA ... The company is also testing a

  • Merck CFO: we’re not only about Keytruda Merck CFO: we’re not only about Keytruda

    He said the performance of other cancer drugs like Lenvima (lenvatinib) and Lynparza (olaparib), revenue from which doubled in the quarter – as well as the vaccine portfolio headed by cervical cancer ... Alliance revenues from Eisai-partnered Lenvima

  • Merck says it has plenty in the pipe beyond Keytruda Merck says it has plenty in the pipe beyond Keytruda

    AstraZeneca-partnered Lynparza (olaparib) and Eisai-partnered Lenvima (lenvatinib) that the company is also expecting to show significant growth in the coming years.

  • Analysts look beyond Keytruda in Merck’s future Analysts look beyond Keytruda in Merck’s future

    Human papillomavirus (HPV) vaccine Gardasil was up a third to $835m, and there were good performances for cancer drugs Lynparza (olaparib) and Lenvima (lenvatinib), partnered with AstraZeneca and Eisai, respectively. ... Responding, the CEO said: “We

  • Eisai’s Lenvima wins European liver cancer indication Eisai’s Lenvima wins European liver cancer indication

    Lenvima however, is already on the European market to treat thyroid cancer, but thanks to positive data from the phase III REFLECT study, Eisai can now add another string to the ... Additionally, Lenvima also demonstrated statistically significant

More from news
Approximately 9 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics